Table 1.
CVD Expenditures and Cost-Effectiveness Findings by Spending Category
| Expenditures by Year ($ Billions)
|
Annual Growth | # of CEA Studies | Studies/$B Spending | Median $/QALY | |||
|---|---|---|---|---|---|---|---|
| 1996 | 2002 | 2008 | |||||
| Treatment | $ 133.6 | $ 166.6 | $ 234.4 | 4.8% | 262 | 1.12 | $ 22,625 |
| Heart conditions | $ 81.0 | $ 94.2 | $ 137.1 | 4.5% | 193 | 1.41 | $ 27,517 |
| Coronary Heart Disease | $ 53.5 | $ 55.2 | $ 82.6 | 3.7% | 88 | 1.06 | $ 22,113 |
| Congestive Heart Failure | $ 12.3 | $ 17.6 | $ 24.7 | 6.0% | 31 | 1.26 | $ 49,637 |
| Dysrhythmias | $ 12.6 | $ 16.4 | $ 24.4 | 5.6% | 30 | 1.23 | $ 48,183 |
| Cerebrovascular disease | $ 22.9 | $ 24.0 | $ 38.0 | 4.3% | 41 | 1.08 | $ 12,427 |
| Prevention | $ 22.1 | $ 43.3 | $ 68.3 | 9.9% | 97 | 1.42 | $ 16,866 |
| Hypertension | $ 13.3 | $ 24.0 | $ 30.5 | 7.2% | 25 | 0.82 | $ 5,754 |
| Hyperlipidemia | $ 4.0 | $ 11.5 | $ 26.9 | 17.1% | 9 | 0.33 | $ 31,614 |
| Total | $ 155.7 | $ 210.0 | $ 302.8 | 5.7% | 359 | 1.19 | $ 20,555 |